Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for Pruritic Genetic Inflammatory Skin Disorders
NCT05649098Phase 1Recruiting
- Sponsor
- Northwestern University
- Start
- Jun 2023
- Primary completion
- Jun 2031
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dupilumab, sponsored by Northwestern University. Primary endpoint: Change in Itch at 16 weeks. Started Jun 2023; status: recruiting.
02
Drugs
Beyond the preview
Go deeper on NCT05649098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05649098.